Concerns exist as to whether the insertion of copper and levonorgestrel-releasing intrauterine devices (IUDs) increases the risk of pelvic inflammatory disease (PID) among women with sexually transmitted infection (STI). We searched the MEDLINE database for all articles published between January 1966 and March 2005 that included evidence relevant to IUDs and STIs and PID. None of the studies that examined women with STIs compared the risk of PID between those with insertion or use of an IUD and those who had not received an IUD. We reviewed indirect evidence from six prospective studies that examined women with insertion of a copper IUD and compared risk of PID between those with STIs at the time of insertion with those with no STIs. These studies suggested that women with chlamydial infection or gonorrhea at the time of IUD insertion were at an increased risk of PID relative to women without infection. The absolute risk of PID was low for both groups (0 -5% for those with STIs and 0 -2% for those without).
Introduction
Approximately 160 million women worldwide use intrauterine devices (IUDs), making the IUD the most popular contraceptive method after sterilization [1] . IUDs are safe and highly effective, long-acting methods of contraception. Theoretical concerns exist, however, as to whether women who have sexually transmitted infections (STIs) and who are therefore at risk of developing pelvic inflammatory disease (PID) further increase their risk of PID with the insertion and use of IUDs. The majority of cases of PID are caused by sexually transmitted microorganisms, with endogenous flora of the lower genital tract playing a lesser role [2] . It is hypothesized that when an IUD is inserted, sexually transmitted microorganisms that may be present in the endocervical canal could be transported to the uterine cavity [3] .
We conducted this systematic review in preparation for an Expert Working Group of international family planning experts convened by the World Health Organization (WHO) in October 2003 to develop and revise medical eligibility criteria for contraceptive use. In this report, we describe the evidence obtained through our systematic review regarding whether insertion and use of a copper or levonorgestrelreleasing IUD increases the risk of PID among women with STIs; we also provide the WHO recommendations that were derived in part from this evidence.
Materials and methods
We searched the MEDLINE database for all articles (in all languages) published in peer-reviewed journals between January 1966 and March 2005, for evidence relevant to the insertion and use of copper and levonorgestrel-releasing intrauterine devices and STIs and PID. The following search strategy was used: [mirena.mp. or levonorgestrel.mp. and (exp intrauterine devices/ or (iud or iucd or ius).mp. or (intrauterine adj3 system).mp. or (intra-uterine adj3 sys- tem).mp. or (intrauterine adj3 device).mp. or (intra-uterine adj3 device).mp.) or exp intrauterine devices/ or (iud or iucd or ius).mp. or (intrauterine adj3 system).mp. or (intra-uterine adj3 system).mp. or (intrauterine adj3 device).mp. or (intrauterine adj3 device We searched reference lists from articles identified by the search, as well as key review articles, to identify additional articles. We did not try to identify unpublished articles or abstracts from scientific conferences. In an attempt to locate additional articles, we contacted an expert in the field but did not learn of any other published literature.
Selection of studies
The search strategy identified a total of 365 articles that considered IUDs as well as STIs and PID. Our primary goal was to identify studies that examined whether, among women with STIs, the insertion and use of copper or levonorgestrel-releasing IUDs increased the risk of PID over that of non-IUD users. After reviewing the titles and abstracts of these articles as well as the full article when necessary, we did not identify any studies that met these criteria. When we looked for indirect evidence that could help us assess our study question, we identified six studies that examined women who received a copper IUD and assessed whether women with STIs at the time the device was inserted had a greater risk of PID than women without STIs at the time of insertion [4] [5] [6] [7] [8] [9] . We contacted one author to clarify whether screening for STI occurred before or after insertion in the author's study. We did not identify any direct or indirect evidence that examined the use of levonorgestrelreleasing IUDs among women with STIs and risk of PID.
Assessment of the study quality and synthesis of the data
We summarized and systematically assessed the evidence through the use of standard abstract forms [10] . We assessed the quality of each individual piece of evidence using a preliminary draft of the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system (Appendix A) [11] .
Because six studies reported percentages of women with STIs and PID, crude relative risks were calculated from the study reports for this systematic review (Table 1) . We assessed heterogeneity by examining the characteristics of the participants included in each study. We did not calculate a summary statistic for PID because of the heterogeneity of the studies, but summary graphs of the relative risks are included in this review ( Figs. 1 and 2 ). We have also included evidence that summarizes the studies reviewed (Table 2 ).
Results
We did not identify any studies that examined whether copper or levonorgestrel-releasing IUD insertion or use modified the risk of PID among women with STIs, i.e., studies that examined a group of women with current STIs and compared the risk of PID in women who had an IUD inserted with women who did not undergo IUD insertion. We did not identify any studies regarding levonorgestrelreleasing IUDs either.
In the absence of direct evidence, we identified six studies that provided indirect evidence, i.e., they examined whether women who had an STI at the time of copper IUD insertion were at a greater risk of developing PID than women without an STI at the time of IUD insertion (Table 1 ) [4 -9] . These studies varied substantially in their design and methodology. Three were prospective studies whose primary goal was to evaluate screening for STIs prior to IUD insertion [4, 5, 7] . The three others were randomized controlled trials evaluating either the use of antibiotics or the placement of strings of the IUD as approaches to decrease PID among women receiving the device; for our purposes, however, we considered these to be prospective observational studies, as we used the presence of an STI at time of IUD insertion as the bexposureQ and development of PID as the outcome [6, 8, 9] . All six studies reported rates of PID following IUD insertion; three of the studies did not provide or describe diagnostic criteria for PID [4, 7, 8] . The degree of screening for STI risk to determine eligibility for inserting an IUD differed among studies, with four studies using some type of syndromic screening [4 -6,8] ; two of these studies also used behavioral risk assessment [4, 5] . Two of the six studies did not report details of their criteria for screening and exclusion [7, 9] . Three studies tested for cervical chlamydial infection only [4, 7, 8] , and the rest for both chlamydial infection and gonorrhea [5, 6, 9] . In four of the studies, results of STI testing were obtained after insertion [4, [6] [7] [8] ; in one, laboratory results were obtained either before or after insertion [9] ; and in one, testing for STIs was done at the first month follow-up visit [5] . In that study, it was assumed that because study participants were at low risk of developing STIs, the majority of women who tested positive (32 women) most likely acquired infection before the IUD was inserted (Morrison CS, FHI, June 4, 2003) . Follow-up from the time of IUD insertion ranged from 1 month to 2 years. As shown in Table 1 and Fig. 1 , the prevalence of STIs and incidence of PID were low in all studies, producing wide variability in the confidence intervals. Rates of diagnosed PID ranged from 0% to 5% among women with STIs at IUD insertion and 0% to 2% for those without STIs at IUD insertion. One of the studies, however, also identified a possible case in a woman with STI at insertion (the woman had lower abdominal pain but no fever); if this case is included, the upper boundary of PID among those with STI would be 10.5% [4] . With the exception of the study of Skjeldestad et al. [7] that observed no cases of PID in the study population, all of the studies observed a greater risk of PID among women with STIs (combining gonorrhea and chlamydial infection) at IUD insertion than women with no STI at insertion, with crude relative risks ranging from 1.63 to 46.35. The Sinei et al. [6] study, which had the largest sample size of the studies and a high follow-up rate, yielded a relative risk of 2.69 (95% CI 1.11-6.53). Fig. 2 shows results for chlamydial infection and gonorrhea separately and also suggests a trend of greater risk of PID with infection, although the number of cases was quite low, leading to imprecise estimates.
Discussion
There are theoretical concerns that, among women with current STIs, the process of inserting an IUD and perhaps the presence of the device may facilitate the ascendance of sexually transmitted organisms from the lower to the upper genital tract. This review found no studies that were able to examine appropriate case and comparison groups to assess this question and, correspondingly, to determine whether among women with STIs the insertion and use of an IUD increases the risk of PID. Of six studies that provided indirect evidence, current STI at the time of IUD insertion increased the risk of PID, albeit only two of the increases were statistically significant [4] [5] [6] [7] [8] [9] . This finding is expected, as gonorrhea and chlamydial infection are the major etiologic agents for PID in women who do not use the IUD. We do not know, however, whether this increase in risk is the same or greater than the risk for PID among women who do not undergo IUD insertion. We do know that the absolute risk of PID remained low among women who had an STI when their IUD was inserted, in the range of 0-5% (or possibly as high as 11%, if the bpossibleQ case of PID was included).
Unfortunately, the overall quality of the indirect studies was bvery low.Q The studies varied in the level of initial screening for STIs and their diagnostic criteria for PID, thereby possibly introducing selection and misclassification bias. Because of the limited number of women with STIs and PID in these studies, assessing possible confounders was not possible. The main limitation of this body of indirect evidence was the small number of cases, which is explained by the current practice of screening for STIs before inserting an IUD and the low prevalence of STIs and incidence of PID in populations desiring IUD insertion.
Ideally, we would like to have evidence from studies that examined the following question: among women with STIs, does insertion of an IUD increase the risk of PID compared with no IUD insertion? Ethically, this study would be difficult to conduct, as women could not be followed, untreated, to assess their risk of developing PID. There is some evidence, however, regarding the risk of PID among women with STIs in the general population who are not IUD users. A study of 129 women with both cervical chlamydial infection and gonorrhea who were treated with penicillin (which does not affect chlamydial infection) found that 9% (11/129) subsequently developed PID [12] . Another study that also treated women having both gonorrhea and chlamydial infection with penicillin found that 30% (6/20) developed PID [13] . Finally, a study of 19 women with gonorrhea found that nine of the women developed PID (four had adenexal tenderness), a median of 11 days after diagnosis of cervical infection [14] . When the risk of developing clinical PID attributable to an IUD was calculated using a model derived from existing studies, the risk was 0.15% when the prevalence of the gonorrhea and chlamydial infection in the population was approximately 10%, and there was screening for genital infections [15] .
Some still argue that the use of an IUD increases the risk of PID regardless of whether STIs are present. Indeed, a meta-analysis that identified 36 papers published between 1974 and 1990 concluded that there was a positive association between IUD use and PID, even in subgroups examining IUDs that were not Dalkon Shields, and when separating symptomatic and asymptomatic PID [16] . There are several biases inherent in observational studies of this question [3, 17] , however, which cannot be resolved through meta-analysis. First, it is difficult to identify a valid control group with which to compare IUD users -the use of hormonal methods, barrier methods or sterilization decreases risk of PID, and women who do not use contraceptives may be very different from users with regard to age, parity and sexual risk behaviors. Second, a detection bias may be at work, as IUD users may be more likely to be diagnosed (or overdiagnosed) with PID. Third, many studies have not adequately controlled for potential confounding factors, primarily sexual behavior. Therefore, it remains difficult to answer this question with observational study designs.
Even without valid relative risks, absolute rates of PID among IUD users are reported to be low. In a 5-year follow-up study in eight developing countries, the rate of acute PID among users of the copper IUD was 0.6 per 1000 womanyears [18] . In randomized controlled trials of prophylactic use of antibiotics at IUD insertion, PID among the placebo group with IUD insertion has been rare, even in populations with high background prevalence of STIs -1.11% in Nigeria at 30 days after insertion [19] and 1.9% in Kenya at 1 month after insertion [6] .
In summary, the study findings consistently showed that women with STIs have a greater risk of PID than women with no STIs when an IUD is inserted, but the absolute risk of PID among women with STIs at the time of IUD insertion is low. We have no information to determine whether the risk of PID among women with STIs who do not receive an IUD is of the same magnitude. Therefore, whether IUDs increase the risk of PID in women with STI at the time of insertion is not known.
In 2003, the WHO Expert Working Group reviewed this evidence to evaluate current medical eligibility criteria for use of copper and levonorgestrel-releasing IUDs [20] . The Expert Working Group recommended that women with current purulent cervicitis or cervical chlamydial infection or gonorrhea should not have an IUD inserted (WHO Category 4), but women who already have an IUD in place and are found to have a cervical infection can generally continue use of the copper or levonorgestrel-releasing IUD (WHO Category 2). Women with other STIs (excluding women with hepatitis desiring the levonorgestrel-releasing IUD, because of concerns regarding hormonal effects on the course of disease) and women with vaginitis can generally initiate and continue use of copper or levonorgestrelreleasing IUDs (WHO Category 2).
